Profile data is unavailable for this security.
About the company
Flerie AB, formerly InDex Pharmaceuticals Holding AB, is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company is an active long-term global biotech and pharmaceutical investor that managing a portfolio of companies in Europe, Israel, and the US. Flerie invests in companies across the entire value chain, providing exposure to opportunities across three segments: Product Development, Commercial Growth, and Limited Partnerships. The Product Development segment consists of early-stage biotech and pharma companies in product development. The Commercial Growth segment consists of companies that are already selling products or services and showcasing proof-of-concept with high growth and some that have already reached profitability. The Limited Partnerships segment provides benefits for the other two segments, including co-investment opportunities, and derisks Flerie’s investment portfolio.
- Revenue in SEK (TTM)100.00k
- Net income in SEK-269.52m
- Incorporated2016
- Employees2.00
- LocationFlerie ABSkeppsbron 16STOCKHOLM 111 30SwedenSWE
- Phone+46 812203850
- Fax+46 850884739
- Websitehttps://www.flerie.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Magle Chemoswed Holding AB | 206.19m | 16.75m | 713.99m | 78.00 | 25.02 | 0.8601 | 17.96 | 3.46 | 1.55 | 1.55 | 19.09 | 45.11 | 0.365 | 0.3327 | 8.15 | 2,643,474.00 | 2.96 | 2.52 | 3.92 | 3.52 | 88.98 | 85.67 | 8.12 | 3.92 | 0.4894 | 4.19 | 0.2994 | -- | 17.00 | 9.97 | 33.07 | -- | -6.34 | -- |
| IRLAB Therapeutics AB | 50.62m | -112.72m | 714.68m | 32.00 | -- | 18.82 | -- | 14.12 | -2.17 | -2.17 | 0.9759 | 0.7332 | 0.2916 | -- | 3.58 | 1,946,769.00 | -64.93 | -27.12 | -118.29 | -30.42 | -138.17 | -72.18 | -222.69 | -155.57 | -- | -21.72 | 0.6132 | -- | -90.71 | 216.07 | -56.82 | -- | -22.56 | -- |
| Vistin Pharma ASA | 412.71m | 59.79m | 1.18bn | 77.00 | 19.73 | 3.90 | 15.07 | 2.86 | 1.38 | 1.38 | 9.55 | 7.01 | 1.09 | 1.89 | 7.27 | 5,501,130.00 | 15.85 | 1.73 | 19.26 | 2.11 | 64.84 | 58.92 | 14.49 | 2.36 | 1.06 | 21.05 | 0.0178 | -- | 51.35 | 16.95 | 1,066.84 | -- | -0.1922 | -- |
| Photocure ASA | 500.39m | 12.51m | 1.35bn | 102.00 | 110.00 | 2.78 | 33.23 | 2.70 | 0.4655 | 0.4655 | 18.98 | 18.43 | 0.7233 | 0.8802 | 7.86 | 5,035,059.00 | 1.81 | -3.06 | 2.01 | -3.54 | 94.52 | 93.64 | 2.50 | -5.15 | 5.30 | -- | 0.00 | -- | 27.35 | 22.50 | 101.36 | -- | 49.83 | -- |
| Probi AB | 630.39m | 10.88m | 3.10bn | 157.00 | 284.75 | 2.27 | 27.65 | 4.92 | 0.9552 | 0.9552 | 55.33 | 120.07 | 0.4049 | 3.24 | 7.14 | 3,939,931.00 | 0.6991 | 4.64 | 0.7409 | 4.98 | 33.18 | 42.04 | 1.73 | 9.83 | 4.83 | -- | 0.0561 | 21.42 | 1.52 | 0.7684 | -58.60 | -26.09 | 31.01 | -- |
| Flerie AB | 100.00k | -269.52m | 3.51bn | 2.00 | -- | 0.8243 | -- | 35,129.88 | -22.07 | -22.07 | 0.0019 | 54.59 | 0.00004 | -- | -- | 14,285.71 | -11.53 | -37.64 | -11.69 | -41.14 | -92,017.00 | -450.51 | -269,618.00 | -454.62 | -- | -2.58 | 0.0002 | -- | -- | 277.02 | 5.05 | -- | -- | -- |
| Swedencare AB (publ) | 2.47bn | 76.20m | 7.37bn | 559.00 | 96.70 | 0.9593 | 18.87 | 2.98 | 0.4801 | 0.4801 | 15.58 | 48.39 | 0.2428 | 2.26 | 8.69 | 5,087,037.00 | 0.7483 | 1.38 | 0.7727 | 1.43 | 56.76 | 55.34 | 3.08 | 5.10 | 1.67 | 2.42 | 0.1726 | 45.33 | 27.48 | 88.16 | -37.96 | 20.24 | 30.90 | -- |
| BioGaia AB | 1.36bn | 336.82m | 10.56bn | 222.00 | 32.51 | 6.77 | 25.89 | 7.79 | 3.33 | 3.33 | 13.42 | 16.01 | 0.6442 | -- | -- | 6,455,538.00 | 16.00 | 15.47 | 17.73 | 16.93 | 73.59 | 73.30 | 24.85 | 27.70 | -- | -- | 0.00 | 104.42 | 17.44 | 11.81 | -2.25 | 11.20 | 29.27 | 28.10 |
| Holder | Shares | % Held |
|---|---|---|
| Fj�rde AP-fondenas of 30 Jun 2024 | 5.46m | 7.00% |
| Atlant Fonder ABas of 30 Aug 2024 | 1.07m | 1.37% |
| SEB Investment Management ABas of 30 Sep 2024 | 106.72k | 0.14% |
| Ponderus Invest ABas of 31 Dec 2023 | 62.00k | 0.08% |
| FCG Fonder ABas of 30 Sep 2024 | 30.67k | 0.04% |
| Baader Bank AG (Investment Management)as of 31 Jul 2024 | 0.00 | 0.00% |
